Finnish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Bariatric Embolization of Arteries for the Treatment of Obesity

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
Linkki tallennetaan leikepöydälle
TilaValmistunut
Sponsorit
Johns Hopkins University
Yhteistyökumppanit
Icahn School of Medicine at Mount Sinai

Avainsanat

Abstrakti

The purpose of this study is evaluate the safety and effectiveness of bariatric embolization as a minimally-invasive image-guided procedure for morbid obesity. In this procedure, specific blood vessels to the stomach are blocked in order to suppress some of the body's signals for feeling hungry, leading to weight loss.
Morbid obesity is currently treated with diet and exercise, medications, and surgery. This study is designed to help treat obesity using a minimally invasive, non-surgical, angiographic (through the blood vessel) approach. This procedure is similar to a common procedure used to treat bleeding within the stomach. This version of the procedure has been named "bariatric embolization".
Although there are over 40 hormones that limit food intake, there is only one hormone, ghrelin that has been shown to stimulate (prompt) food intake. In obese patients, eating fails to suppress ghrelin levels, which is believed to prevent feeling full after a meal and to lead to overeating. Due to the strong hunger craving effects of ghrelin, this hormone has been a target for the treatment of obesity and weight loss. More recently, ghrelin has been shown to have a significant role in the long-term effect of weight loss in bariatric (obesity) surgery where ghrelin levels are shown to be much lower when compared to untreated patients.
Recent data collected in animals in has shown that blocking blood vessels to a particular portion of the stomach (bariatric embolization) can temporarily decrease levels of the appetite inducing hormone ghrelin, and decrease short-term weight gain. In a study of 5 people, there was a decrease in ghrelin levels and weight loss in the first month after the procedure, but there is no information about the effects of the procedure over longer periods of time.
The investigator hopes to learn if bariatric embolization results in safe and effective weight loss in people who are morbidly obese.

Päivämäärät

Viimeksi vahvistettu: 10/31/2018
Ensimmäinen lähetys: 06/10/2014
Arvioitu ilmoittautuminen lähetetty: 06/12/2014
Ensimmäinen lähetetty: 06/16/2014
Viimeisin päivitys lähetetty: 10/31/2018
Viimeisin päivitys lähetetty: 11/04/2018
Ensimmäisten tulosten toimittamispäivä: 09/23/2018
Ensimmäisten QC-tulosten toimittamispäivä: 10/31/2018
Ensimmäisten tulosten päivämäärä: 11/04/2018
Todellinen opintojen alkamispäivä: 05/31/2014
Arvioitu ensisijainen valmistumispäivä: 11/30/2017
Arvioitu tutkimuksen valmistumispäivä: 02/28/2018

Ehto tai tauti

Morbid Obesity

Interventio / hoito

Device: Intervention/Bariatric Embolization

Vaihe

-

Varren ryhmät

VarsiInterventio / hoito
Experimental: Intervention/Bariatric Embolization
Device: Intervention/Bariatric Embolization
Embosphere Microspheres

Kelpoisuusehdot

Tutkimukseen soveltuvat iät 18 Years Vastaanottaja 18 Years
Sukupuolet, jotka ovat kelpoisia tutkimukseenAll
Hyväksyy terveelliset vapaaehtoisetJoo
Kriteeri

Inclusion Criteria:

1. Willing, able and mentally competent to provide written informed consent.

2. Body mass index (BMI) between 40-60.

3. Residence within 25 miles of the enrolling institution

4. Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist amenable to Bariatric Embolization, as assessed on 3D CT angiography.

5. Suitable for protocol therapy as determined by the interventional radiology Investigator.

6. Adequate hematological, hepatic and renal function as follows:

Hematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L International Normalized Ratio (INR) <1.5

Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L

Renal Estimated Glomerular Filtration Rate (GFR) > 60ml/min.1.73m2

7. Aged 18 years or older.

Exclusion Criteria:

1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery

2. Prior radiation to the upper abdomen

3. Prior embolization to the stomach, spleen or liver

4. Portal venous hypertension

5. Prior or current history of peptic ulcer disease

6. Hiatal Hernia

7. Significant risk factors for peptic ulcer disease including daily NSAID use and smoking.

8. Active H. Pylori infection

9. Weight greater than 400 pound

10. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of < 60 milliliters per minute

11. Major comorbidity such as cancer, significant cardiovascular disease, diabetes, or peripheral arterial disease.

12. Complicated arterial anatomic variants including left gastric artery arising from the aorta, and/or hepatic arterial supply via a replaced or accessory left hepatic artery arising from the left gastric artery.

13. Pregnancy

14. Preexisting chronic abdominal pain

15. Positive stool occult study

16. Abnormal Endoscopy

17. Abnormal Nuclear Gastric Motility examination

18. American Society of Anaesthesiologists (ASA) Class 4 or 5 (very high risk surgical candidates: class 4= incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study will be excluded from participation. This exclusion criterion exists because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects.

19. History of Inflammatory Bowel Disease

20. Autoimmune disease

21. Cirrhosis

22. Known history of allergy to iodinated contrast media

Tulokset

Ensisijaiset tulosmittaukset

1. Percent Weight Change [12 Months]

This will be assessed by Percentage of excess weight loss (EWL). Percentage of excess weight loss is calculated by measuring the participants excess weight at baseline and then calculating the percentage of excess weight that was lost 12 months after surgery (for example if a participant has 100 pounds of excess weight prior to surgery and loses 30 pounds, their excess weight loss would be 30%).

Muut lopputulokset

1. Blood Pressure [12 Months]

Unit of Measure: mmHg

2. Lipid Panel [12 Months]

Unit of Measure: mg/dL, Total cholesterol, High-density lipoprotein cholesterol (HDL-C) - often called "good cholesterol" , Low-density lipoprotein cholesterol (LDL-C) - often called "bad cholesterol" and Triglycerides

3. Ghrelin Levels [12 Months]

Unit of Measure: pg/mL, Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation.

4. Serum Obesity Hormone(Leptin) [12 Months]

This will be assessed by Leptin concentration Unit of Measure: pg/mL, Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss.

5. Eating and Hunger/Satiety Assessments [12 Months]

Unit of Measure: N/A Utilizing 3-Factor Eating Questionnaire Scores

6. Quality of Life Parameters Survey [12 Months]

Unit of Measure: N/A Utilizing Short Form Health Survey (SF)-36 and Impact of Weight on Quality of Life (IWQOL)-Lite

7. Food Intake [12 Months]

Documented via journal entries

8. Results From Endoscopy [12 Months]

Photos and clinical reports analyzed

9. Gastric Motility/Emptying [12 Months]

Unit of Measure: (t 1/2) in minutes, A gastric emptying scan (GES) is a nuclear medicine exam that uses a radioactive material that you will eat in a meal. You will eat this meal in the Radiology department before your scan. The radioactive material allows doctors to see how your stomach empties. This scan is used to help diagnose conditions called motility disorders. These are conditions that change the way the stomach contracts and moves food into your intestines. A GES is a form of radiology, because radiation is used to take pictures of your body.

Liity facebook-sivullemme

Täydellisin lääketieteellinen tietokanta tieteen tukemana

  • Toimii 55 kielellä
  • Yrttilääkkeet tieteen tukemana
  • Yrttien tunnistaminen kuvan perusteella
  • Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
  • Lue hakuusi liittyviä tieteellisiä julkaisuja
  • Hae lääkekasveja niiden vaikutusten perusteella
  • Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen

Google Play badgeApp Store badge